Re: BMY nuke
GILD is the obvious winner for now (but this may change overnight if any of the various GS7977 programs show a safety signal). If anything, I think this makes non-nuke programs more valuable going forward, including ABT's.
On a related note, I think people may unduly punish BMY today forgetting daclatasvir, asunaprevir and lambda which still comprise a very enviable HCV portfolio. And their willingness to partner (unlike GILD) is clearly a risk-mitigating element. But some degree of punishment for throwing 2.5B down the drain is clearly warranted.
Market Data 
Markets 
AI
